Picture of IX Biopharma logo

42C IX Biopharma Share Price

0.000.00%
sg flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapMomentum Trap

Momentum

Relative Strength (%)
1m-13.65%
3m-3.89%
6m-5.74%
1yr-14.46%
Volume Change (%)
10d/3m+54.99%
Price vs... (%)
52w High-41.79%
50d MA-4.98%
200d MA-15.69%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value4.65
Price to Tang. Book4.72
Price to Free Cashflow63.97
Price to Sales8.84
EV to EBITDA80.89

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-4%
Return on Equity-8.13%
Operating Margin-8.78%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202230th Jun 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of IX Biopharma EPS forecast chart

Profile Summary

IX Biopharma Ltd. is a Singapore-based specialty pharmaceutical and nutraceutical company. The Company is focused on the development and commercialization of therapies for diseases of the central nervous system using patent protected formulations for sublingual delivery. It developed a patented drug delivery platform technology, WaferiX. WaferiX delivers drug sublingually via the mucosa for better absorption, faster onset of action and predictable effect. Its delivery platform is particularly useful for drug repurposing. The Company operates in two segments, namely Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and nutraceutical products. Nutraceutical primary business activities are the sale of nutraceutical products. The Company's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.

Directors

Last Annual
June 30th, 2021
Last Interim
December 31st, 2021
Incorporated
May 8th, 2004
Public Since
January 1st, 1970
No. of Shareholders
1,983
No. of Employees
56
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
sg flag iconSingapore Exchange Securities Trading Ltd
Shares in Issue
764,899,934
Blurred out image of a map
Address
1 Kim Seng Promenade, 237994
Web
http://www.ixbiopharma.com/
Phone
+65 62352270
Auditors
PricewaterhouseCoopers LLP

42C Share Price Performance

Upcoming Events for 42C

IX Biopharma Ltd Annual Shareholders Meeting

Similar to 42C

Picture of Haw Par logo

Haw Par

sg flag iconSingapore Exchange Securities Trading Ltd

Picture of Hyphens Pharma International logo

Hyphens Pharma International

sg flag iconSingapore Exchange Securities Trading Ltd

Picture of Pharmesis International logo

Pharmesis International

sg flag iconSingapore Exchange Securities Trading Ltd

Picture of Suntar Eco-City logo

Suntar Eco-City

sg flag iconSingapore Exchange Securities Trading Ltd

FAQ

Or unlock with your email

Or unlock with your email